IQVIA (NYSE:IQV) Given New $265.00 Price Target at Truist Financial

IQVIA (NYSE:IQV) had its price target lowered by Truist Financial from $286.00 to $265.00 in a research note published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the medical research company’s stock.

IQV has been the topic of several other reports. Robert W. Baird decreased their target price on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price target for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. BTIG Research reduced their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, TD Cowen cut their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $259.13.

IQVIA Price Performance

NYSE:IQV opened at $217.68 on Monday. IQVIA has a 52 week low of $190.20 and a 52 week high of $261.73. The firm has a market cap of $39.51 billion, a price-to-earnings ratio of 28.57, a P/E/G ratio of 2.15 and a beta of 1.51. The firm’s 50-day simple moving average is $232.31 and its 200 day simple moving average is $229.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by insiders.

Institutional Investors Weigh In On IQVIA

Institutional investors have recently added to or reduced their stakes in the business. Capital Performance Advisors LLP purchased a new stake in IQVIA during the third quarter valued at about $27,000. Park Place Capital Corp purchased a new stake in IQVIA during the third quarter valued at about $28,000. Versant Capital Management Inc lifted its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA during the second quarter valued at about $27,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA during the second quarter valued at about $29,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.